Trade accounts receivable comprise gross contractual amounts due of CHF 7.1 million (2014: CHF 1.3 million), of which CHF 0.5 million (2014: CHF 0.1 million) was expected to be uncollectable at the acquisition date.

The acquisitions were accounted for using the acquisition method. The resulting goodwill includes expected synergies from the acquisition, the work force and potentially other intangible assets that could not be valued separately. It is not expected to be deductible for tax purposes. The initial accounting for the acquisition in the current financial year is provisional and subject to change regarding the recognized deferred tax asset from tax loss carry-forwards in the amount of CHF 2.4 million. Further analysis has to be performed in order to confirm the measurement of the amount.

The Group acquired 100 % of the voting rights of Sias-Xiril Group on November 30, 2015 consisting of the following companies:

The Sias-Xiril Group develops, manufactures and sells a wide range of modular and complete laboratory automation solutions to OEM-partners. The acquired Group is part of the business segment ‘Partnering Business’.

The Group acquired 100 % of the voting rights of IBL International Group on July 30, 2014 consisting of the following companies:

The IBL International Group develops, manufactures and sells a comprehensive portfolio of immunoassays for the life science research and routine clinical diagnostics. The acquired Group is part of the business segment ‘Life Sciences Business’.

1. In determining these amounts, management has assumed that the fair value adjustments that arose on the acquisition date would have been the same if the acquisition had occurred on January 1, 2015 and 2014, respectively.